Loading...
XNASENTO
Market cap1mUSD
Dec 24, Last price  
0.63USD
1D
2.05%
1Q
94.68%
IPO
-78.77%
Name

First Wave BioPharma Inc

Chart & Performance

D1W1MN
XNAS:ENTO chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
114.82%
Rev. gr., 5y
%
Revenues
0k
Net income
-16m
L-4.74%
-5,930,236-14,591,662-11,096,383-13,533,617-15,611,625-38,723,510-59,078,185-16,581,218-15,794,983
CFO
-12m
L-44.60%
00-4,510,778-4,534,859-7,184,638-10,869,320-14,033,502-11,221,538-32,288,218-22,344,079-12,377,852
Earnings
Mar 27, 2025

Profile

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
IPO date
Oct 11, 2016
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
15,771
12,784
57,242
Unusual Expense (Income)
NOPBT
(15,771)
(12,784)
(57,242)
NOPBT Margin
Operating Taxes
(4)
1,952
540
Tax Rate
NOPAT
(15,771)
(14,736)
(57,783)
Net income
(15,795)
-4.74%
(16,581)
-71.93%
(59,078)
52.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
23,296
26,168
BB yield
-529.18%
Debt
Debt current
680
670
719
Long-term debt
294
494
700
Deferred revenue
Other long-term liabilities
7,000
Net debt
(2,759)
(221)
(6,829)
Cash flow
Cash from operating activities
(12,378)
(22,344)
(32,288)
CAPEX
(500)
(10,319)
Cash from investing activities
(500)
(10,319)
Cash from financing activities
15,227
15,740
44,763
FCF
(15,442)
1,176,241,553
(1,176,321,584)
Balance
Cash
3,712
1,363
8,249
Long term investments
22
22
Excess cash
3,733
1,384
8,249
Stockholders' equity
(184,329)
(168,534)
(155,127)
Invested Capital
188,758
172,159
155,336
ROIC
ROCE
EV
Common stock shares outstanding
336
36
Price
4.20
-96.57%
122.58
-97.98%
6,069.00
-85.10%
Market cap
1,413
-67.91%
4,402
 
EV
(1,347)
4,182
EBITDA
(15,742)
(12,755)
(56,700)
EV/EBITDA
0.09
Interest
16
11
Interest/NOPBT